Compare TransMedics Group Inc (TMDX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vistra Corp — how do they compare? TransMedics Group Inc trades at $86.78 (market cap $3.10B), while Vistra Corp trades at $147.01 (market cap $48.64B). The key difference: Vistra Corp is far larger — about 15.7× TransMedics Group Inc's market cap, and Vistra Corp pays a 0.63% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | VST | |
|---|---|---|
Market Cap | $3.10B | $48.64B |
Sector | Technology | Technology |
52-Week High | $150.42 | $217.92 |
52-Week Low | $61.99 | $134.71 |
Enterprise Value | $3.49B | $70.58B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
VST trades at $147.54, up 3.27% today, with strong analyst support (90.9% buy ratings) and a $239.75 consensus price target suggesting 62% upside. Recent Q2 2026 earnings showed mixed results with an EPS miss but 30% EBITDA growth to $1.77 billion, driven by data center demand. Technical indicators are bearish with support at $141, while fundamentals show robust profitability (11.55% net margin) offset by high valuation multiples (P/E 24.44).
The outlook remains positive given Vistra's positioning in the AI-powered data center boom, though risks include ERCOT pricing volatility and hedging losses. With institutional ownership stable and dividend payments consistent, the stock offers growth exposure to electricity demand trends, but investors should monitor execution on 2026 guidance and competitive pressures in the utility sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
